Cellectis S.A.
Cellectis S.A. (CLLS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CLLS · as of Jun 8, 2026
Key Statistics
Explore Cellectis S.A. Data
clls stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 17 · Buy rate: 82.4%
The CLLS analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month price target is $9.00, representing +207.17% upside from the current price of $2.93.
Competitors & Peers
clls competitorsCLLS
ACIU
ALDX
AMRN
ANRO
DBVTStock Performance
Full HistoryAbout Cellectis S.A.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express …
what is cellectis s.a. · clls stock overview · cellectis s.a. company profile · who is cellectis s.a. ceo · clls NASDAQ · cellectis s.a. headquarters · cellectis s.a. business segments
About Stock Overview & Key Data
Cellectis S.A. (CLLS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 24, 2015. As of the latest trading session, CLLS stock price is $2.93, with a market capitalization of $294.2M. The stock has returned +104.90% over the past 12 months and -39.46% year-to-date.
According to 17 Wall Street analysts, the consensus rating for Cellectis S.A. stock is Buy, with an average 12-month price target of $9.00. In fiscal year 2025, Cellectis S.A. reported revenue of $72.9M and net income of -$67.6M. For detailed data — including Cellectis S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cellectis S.A. (CLLS) stock price is $2.93. The stock is traded on NASDAQ under the ticker symbol CLLS. The 52-week range is $1.33 – $5.48.